BCG Treatment for Multifocal Low-Grade Papillary Urothelial Carcinoma
For a patient with non-invasive low-grade papillary urothelial carcinoma that is multifocal, you should explain that BCG therapy is NOT the standard first-line treatment—instead, a single immediate intravesical chemotherapy instillation (such as mitomycin C) followed by surveillance is the recommended approach, with BCG reserved only for specific intermediate-risk scenarios. 1
Understanding the Risk Stratification
The presence of multifocality in low-grade disease places this patient in a nuanced position. According to the 2022 ESMO guidelines, patients with low-risk NMIBC (which includes solitary, low-grade Ta tumors <3 cm) should receive single immediate intravesical chemotherapy, not BCG 1. However, the 2025 IBCG consensus defines intermediate-risk (IR-NMIBC) using specific risk factors, and multifocality is one of these key factors 2.
When BCG Is NOT Indicated
In patients with low-grade disease and minimal risk factors, BCG should be avoided due to its side-effect profile without proportionate benefit. The guidelines are explicit:
- Low-risk patients should NOT receive BCG because the toxicity outweighs benefits 2
- Single immediate intravesical chemotherapy reduces 5-year recurrence from 59% to 45% in low-risk disease 1
- Progression risk remains negligible (<2% at 5 years) with chemotherapy alone 1
When BCG May Be Considered
BCG becomes appropriate only when the patient has intermediate-risk disease with multiple IBCG risk factors. The 2025 IBCG guidelines provide a clear algorithm 2:
Risk Factor Assessment (IBCG IR-NMIBC factors):
- Multifocality
- Tumor size >3 cm
- Recurrence within 1 year
- Prior recurrence rate
Treatment Algorithm Based on Risk Factors:
0 risk factors: Single perioperative chemotherapy only 2
1-2 risk factors: Additional adjuvant induction intravesical chemotherapy (or BCG if prior chemotherapy was used) 2
3 risk factors: BCG induction plus 1 year of maintenance can be considered, particularly during adequate BCG supply 2
BCG Regimen When Indicated
If BCG is appropriate for intermediate-risk disease with multiple risk factors, the regimen consists of 1:
Induction phase:
- 6 weekly BCG instillations
Maintenance phase (12 months total):
- 3 BCG instillations at 3 months
- 3 BCG instillations at 6 months
- 3 BCG instillations at 12 months
This 12-month BCG protocol showed a 32% reduction in recurrence risk compared to mitomycin C in intermediate-risk patients, though no significant difference in progression rates was observed 1.
Critical Distinction: Prioritize Chemotherapy Over BCG
The 2025 guidelines explicitly state that in IR-NMIBC patients, intravesical chemotherapy should be prioritized over BCG, especially during BCG shortages 2. This represents an important shift in thinking—BCG is not automatically superior for all intermediate-risk patients.
Common Pitfalls to Avoid
Don't reflexively use BCG for "multifocal" disease without assessing total risk factor burden—multifocality alone in low-grade disease doesn't mandate BCG
Don't skip the immediate perioperative chemotherapy dose—this single instillation provides substantial benefit regardless of subsequent therapy 1, 2
Don't use BCG without maintenance—induction alone is insufficient; the maintenance component is essential for efficacy 1
Don't ignore BCG supply constraints—chemotherapy alternatives are explicitly preferred when BCG availability is limited 2
Side Effects to Discuss
BCG has greater toxicity than chemotherapy 3. Common effects include:
- Local bladder irritation (dysuria, frequency, hematuria)
- Flu-like symptoms (fever, myalgia) lasting 1-2 days 4
- Rare but serious: disseminated BCG infection (0.06-1.56 cases per million doses), which can be fatal 4, 5, 6
Surveillance Strategy
Following treatment, the surveillance schedule is 2:
- First cystoscopy at 3 months
- Every 6 months for 2 years
- Every 6-12 months for years 3-4
- Annually thereafter
Urine cytology is NOT routinely recommended for low-grade disease surveillance due to poor sensitivity 2.